Search Results
Results found for "Novo Nordisk Foundation"
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Indeed, incretin-based drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound are advancing diabetes
- 📰 GPCR Weekly News, July 31 to August 6, 2023
Raised To Discover And Advance Novel Oral Small Molecule Medicines Targeting G Protein-Coupled Receptors Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults
- 📰 GPCR Weekly News, November 13 to 19, 2023
Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence Novo Nordisk Invests 42 Billion Danish Kroner in New Manufacturing Facilities Addex ADX71149 Epilepsy Phase
- AcroScreen co-founder Margaux Duchamp has been selected as a 30 under 30 Europe Forbes ranking 2022
May 2022 "We are thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 under
- John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to ...
April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel
- 📰 GPCR Weekly News, March 11 to 17, 2024
Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy Novo
- GPCR Buzz of the Week | Sep 23 - 29, 2024
Therapeutics with Generative AI Nxera Pharma receives approval of insomnia drug in Japan Lilly and Novo and UK and Announces the Nomination of Clinical Candidate Against MC2 Call for GPCR Papers Deadline: Nov
- Pharmacology Isn't What You Think—It's So Much More
Welcome to Terry’s Corner , where foundational pharmacology is demystified by someone who’s spent over just look at the data—learn how to read the story it’s telling. 👉 Start your journey with Terry’s foundational
- What If Your Data is Lying to You? The Calcium Assay Dilemma
In this foundational lesson, Terry Kenakin dives deep into a widely used, often misunderstood tool in interpretive tools to ask smarter questions, avoid missteps, and use calcium assays with strategic clarity. 📍 Foundational
- 📰 GPCR Weekly News, March 27 to April 4, 2023
31 December 2022 Addex Raises $5.0 Million in Equity Financing Testing the limits of SMILES-based de novo
- Pharmacologic Models
Terry Kenakin’s newest foundational lesson in Terry's Corner cuts straight to it: Why models are vital
- Why Dose-Response Curves Are Pharmacology’s Secret Weapon
In the newest foundational lesson from Terry Kenakin’s Pharmacology Vault , we unlock the visual language
- Unlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
In the foundational lesson of Terry’s Corner , Dr. Terry Kenakin invites us to challenge outdated assumptions and step into a new era of drug discovery.
- Ever Wondered How Drugs Are Discovered?
In this foundational-level lesson, Terry unpacks the real-life process behind discovering new drugs,
- From Ox Liver to AI: How the History of Pharmacology Shapes Its Future
In this exclusive foundational-level lecture, Dr.
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding
- Lab Leadership Without Ego: How Sokhom Pin Built the Happiest Team at Alkermes
It was the foundation for his next opportunity: helping launch Cerevel from the ground up. __________
- Ben Clements on Rescuing Opioids with GPCR Modulators
His work highlights how foundational GPCR science can drive therapeutic innovation.
- Understanding Orthosteric Binding: The Key to Drug Action
This foundational knowledge guides researchers in the development of new therapeutics.
- Job Opportunity Spotlight #1: Principal Scientist, In Vitro Pharmacology
Mark: “Have you found this to be accurate?” Beth: “Yes. Top candidates will have a solid foundation in GPCR pharmacology as well as some experience in drug discovery
- APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking
The research team, led by Brandon Novy and colleagues, utilized an innovative APEX2/AUR biosensor that
- Exscientia is 10 years old this July!
Founded as a spinout from the University of Dundee on 20 July 2012, Exscientia pioneered the design of patients with advanced haematological cancers, international partnerships with pharma and healthcare foundations
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
modulation of isoform- and ligand specific aGPCR functions using unique tools, and thus establishes a foundation
- From Pharmacy Crisis to Scientific Calling: Catherine Demery’s Unfiltered Path into Opioid Research
She found herself drawn toward the science behind the drugs, rather than their clinical application. Catherine’s methodical retention of those skills later gave her a solid foundation in her academic work
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
They’re cracks in the foundation. And cracks don’t stay small for long.
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
While AlphaFold provides an excellent foundation for generating hypotheses in drug discovery, it is not
- Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..
In the experiment, similar sets of residues were found to be in significant contact with both ligands Our results build a strong foundation for further improvement of our approach by rationalizing the kinetics
- Reflections on My PhD Journey: Lessons Learned
The right environment, paired with a supportive supervisor, laid the foundation for a fulfilling and Analyze Your Work as You Go The PhD journey is often compared to a rollercoaster, and I found this to
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Terry Kenakin reframes one of pharmacology’s most foundational ideas: the difference between competitive
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
molecular determinants of ligand efficacy and potency in GPCR signalling, this research provides a foundation